Ivana Mitrevska

Dr. Ivana Mitrevska


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2026 in Acta Pharmaceutica
Verified
Journal Article
Open access
PDF file
IMIvana Mitrevska
Ivana Mitrevska
MCMarina Chachorovska
Marina Chachorovska
GPGjorgji Petrushevski
Gjorgji Petrushevski
During in-use stability testing of cefixime granules for oral suspension, an impurity with a relative retention time of 0.19 was consistently detected and increased during storage. To ensure regulatory compliance and patient safety, the impurity was structurally identified and toxicologically qualified. A laboratory-scale formulation and commercial products were studied under refrigerated and ambient conditions. The impurity was isolated by automated fraction collection and characterised by liquid chromatography-mass spectrometry and tandem mass spectrometry. Kinetic evaluation showed pseudo-first-order formation, with faster accumulation at ambient temperature. The impurity was identified as a γ -lactone degradation product of cefixime, present as multiple stereoisomers stabilised under acidic conditions. In silico toxicological assessment using complementary platforms indicated no additional structural alerts, no mutagenic potential, and negligible acute toxicity. The impurity forms only after prolonged storage of reconstituted suspensions and is classified as an ICH M7 Class 5 impurity, requiring no further genotoxicity testing. The applied analytical-computational workflow provides an efficient approach for impurity qualification in β -lactam antibiotics.

15 May 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
IMIvana Mitrevska
Ivana Mitrevska
ZNZorica Naumovska
Zorica Naumovska
TMTrajce Mitrev
Trajce Mitrev
OPOlivera Paneva
Olivera Paneva
Background/Objectives: Following the market authorization of innovative medicinal products, continuous monitoring of safety signals is essential to ensure a favorable benefit–risk balance. This is particularly relevant for biological therapies used in oncology, where complex mechanisms of action and patient-related risk factors may contribute to rare but serious adverse events. The objective of this paper is to describe and critically evaluate the internal pharmacovigilance processes applied by a pharmaceutical company in response to a potential post-marketing safety signal of stroke associated with a newly authorized biological medicinal product for colorectal cancer. Methods: A structured signal management approach was applied in line with international regulatory guidance. The evaluation included detailed clinical assessment of reported post-marketing cases, review of safety data from completed and ongoing clinical trials, epidemiological comparison with background stroke incidence, assessment of potential risk factors, and review of the pharmacological and biological plausibility. Additional data sources, including scientific literature, safety databases, and periodic safety reports, were systematically reviewed. Multidisciplinary collaboration among pharmacovigilance, medical, and regulatory teams supported the assessment and regulatory interactions. Results: The cumulative evidence did not allow confirmation of a definitive causal relationship between the medicinal product and stroke but identified the event as a potential safety signal requiring close monitoring. The assessment supported the preparation of an evidence-based company position and informed discussions with regulatory authorities, including the European Medicines Agency. Conclusions: This case illustrates the practical implementation of structured signal management in the post-marketing setting. Timely evaluation, interdisciplinary coordination, and regulatory engagement are essential to ensure patient safety, maintain regulatory compliance, and support informed benefit–risk decision-making for innovative biological medicinal products.

1 May 2026 in Current Pharmaceutical Analysis
Verified
Journal Article
Open access
IMIvana Mitrevska
Ivana Mitrevska
LPLena Pislevska
Lena Pislevska
MPMonika Stojanovska Pecova
Monika Stojanovska Pecova

1 June 2026 in Acta Pharmaceutica
Verified
Journal Article
Open access
PDF file
IMIvana Mitrevska
Ivana Mitrevska
DKDino Karpicarov
Dino Karpicarov
AMAna Mihailovska
Ana Mihailovska
DMDejan Mirakovski
Dejan Mirakovski
OPOlivera Paneva
Olivera Paneva
GPGjorgji Petrushevski
Gjorgji Petrushevski
The aim of this study was to evaluate scanning electron microscopy (SEM) combined with energy-dispersive X-ray spectroscopy (EDS) as complementary analytical tools for supporting continuous improvement in pharmaceutical granule manufacturing. Pilot-scale cefixime granules for oral suspension were prepared as defined process scenarios, including placebo, reference, intermediate, stress-exposed, and optimised batches. SEM was used to compare granule morphology, surface integrity, and agglomeration behaviour, whereas EDS provided qualitative and semi-quantitative information on localised elemental composition, with emphasis on sulfur as an API-related marker and oxygen-to--sulfur trends as surface-sensitive indicators of process- or stress-related variability. Intermediate and stress-exposed batches showed increased surface roughness, microstructural deterioration, and higher oxygen-to-sulfur ratios, whereas reference and optimised batches showed more uniform morphology and comparable elemental profiles. The findings indicate that SEM/EDS can provide useful material-level insight into process-related variability and may support root--cause investigation and process refinement. Overall, SEM/EDS is proposed as a complementary, localised, and semi-quantitative approach for supporting continuous improvement in pharmaceutical granule manufacturing.

29 August 2026 in Discover Sustainability
Verified
Journal Article
Open access
PDF file
IMIvana Mitrevska
Ivana Mitrevska
DKDino Karpicarov
Dino Karpicarov
SBSonja Burcevska
Sonja Burcevska
EKElizabeta Karadzinska
Elizabeta Karadzinska
OPOlivera Paneva
Olivera Paneva
Pharmaceutical packaging must protect medicinal product quality and patient safety while responding to increasing pressure to reduce material use, greenhouse-gas emissions, and packaging waste. This structured integrative review examines how the European Union Packaging and Packaging Waste Regulation, life-cycle evidence, material innovation and digital information systems affect pharmaceutical packaging decisions. Peer-reviewed studies, official legislation, standards and regulatory guidance were critically synthesised, while company data were used only when independently verifiable evidence was unavailable and were explicitly labelled as industry evidence. Published life-cycle assessments show that environmental rankings depend strongly on the functional unit, system boundary, dosage format, secondary packaging, energy mix and end-of-life assumptions; therefore, broad claims that a single material consistently delivers fixed carbon reductions are not scientifically transferable. High-density polyethylene, polypropylene, paper-based structures, polylactic acid and cyclic olefin polymers offer specific opportunities, but each presents trade-offs involving barrier variability, pharmaceutical-grade purity, extractables and leachables, sterilisation, forming performance, recycling infrastructure and regulatory requalification. The PPWR introduces important circularity requirements but also includes pharmaceutical-specific derogations, and it does not automatically impose a Digital Product Passport on every medicinal package. Digital product information and traceability may improve accessibility and data availability, although their environmental benefit, interoperability, validation and cybersecurity requirements need further evidence. Sustainable packaging transitions should therefore follow a product-specific benefit-risk approach in which patient protection and product quality remain non-negotiable, and environmental gains are demonstrated through comparable life-cycle and performance data.

22 August 2026 in Journal of Pharmaceutical Innovation
Verified
Journal Article
Open access
IMIvana Mitrevska
Ivana Mitrevska
SBSandra Boshnachki
Sandra Boshnachki
SBSonja Burcevska
Sonja Burcevska
EKElizabeta Karadzinska
Elizabeta Karadzinska
OPOlivera Paneva
Olivera Paneva